| Name | GLPG2938 |
|---|
| Description | GLPG2938 is a potent and selective S1P2 antagonist. GLPG2938 can be used for the research of idiopathic pulmonary fibrosis[1]. |
|---|---|
| Related Catalog | |
| Target |
S1PR2 |
| In Vitro | GLPG2938 (0.5~5 μM; HPF cells) significantly prevents the S1P-mediated contraction at all tested concentrations[1]. |
| In Vivo | GLPG2938 (1~10 mg/kg; p.o.) displays a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score[1]. GLPG2938 shows good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs[1]. Animal Model: Male C57BL/6 mice[1] Dosage: 1~10 mg/kg Administration: P.o. Result: Displayed a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score. |
| References |
| Molecular Formula | C20H19F6N7O2 |
|---|---|
| Molecular Weight | 503.4 |